Immune cell therapy is one of the immunotherapies. In September 107, Taiwan significantly opened up autologous immune cell therapy in accordance with the revised provisions of the "Management Measures for the Implementation or Use of Specific Medical Technology Inspection and Testing Medical Instruments" (hereinafter referred to as the "Special Management Measures"), providing more treatment options for end-stage cancer patients.
The precise biotechnology service is to isolate immune cells from cancer patients or healthy donors (allogeneities), cultivate and activate them in large quantities in legally compliant GMP or GTP grade cell factories, which is different from traditional chemotherapy that extinguishes both cancer cells and healthy cells; We utilize the natural recognition mechanism of immune cells to more accurately extinguish cancer cells. Its side effects are lower than traditional chemotherapy, and its response rate to tumors is significantly improved, promoting prognosis and reducing recurrence rate.
Announcement webpage of special management measures:
https://www.mohw.gov.tw/cp-16-43698-1.html»
The list of treatment hospitals shall be carried out in accordance with the Administrative Measures for the Implementation or Use of Medical Instruments for Specific Medical Technical Inspection
1、Kaohsiung Medical University Affiliated Zhonghe Memorial Hospital
2、Zhongshan Medical Association Legal Person Zhongshan Hospital
3、Tong Comprehensive Medical Association Legal Person Tong Comprehensive Hospital
4、Guangtian Medical Association Legal Person Guangtian General Hospital
5、Buddhist Tzu Chi Medical Foundation, Hualien Tzu Chi Hospital
6、Taipei Third Army General Hospital
(一)Clinical trial of PB103 allogeneic immune cell therapy»
Hematology and Oncology Department of the Third Military General Hospital
Program host: Dr. Dai Mingshen
Co host: Dr. Chen Yuqin, Dr. He Jingliang, Dr. Zhang Pingying
Dr. Chen Jiahong, Dr. Ye Renhua, Dr. Wu Yiying, Dr. Lai Xuewei, Dr. Huang Ziquan
(二)Phase I/II Clinical Trial of PB101 Autoimmune Cell Therapy»
Trial host: Dr. Li Guande, Department of Hematology and Oncology, Affiliated Hospital of Taipei Medical University
Co host: Dr. Zhong Qili, Dr. Zhou Baiqian, Dr. Xiao Shixin
Test host: Dr. Cai Zhenliang, Department of Thoracic Medicine, General Hospital of the Third Army, and Dr. Huang Caiwang, Department of Thoracic Surgery
Co host: Dr. Jian Zhifeng, Dr. Peng Zhongyi, Dr. Shen Zhihao, Dr. Wu Shiwei
Dr. Zhang Shanyue, Dr. Chen Yingjie, Dr. Meng Fanjun, Dr. Liu Jiaxin, Dr
